nach oben

Annals of Hematology

Erschienen in:

01.12.2003 | Original Article

Epigenetic inactivation of INK4/CDK/RB cell cycle pathway in acute leukemias

verfasst von: C. S. Chim, A. S. Y. Wong, Y. L. Kwong

Erschienen in: Annals of Hematology | Ausgabe 12/2003

Einloggen, um Zugang zu erhalten

Abstract

Dysregulation of cell cycle is important in oncogenesis. We analyzed the inactivation of the INK4 family CKI/CDK/RB pathway by gene promoter hypermethylation in leukemogenesis. The methylation-specific polymerase chain reaction (MSP) with primers for methylated (M-MSP) and unmethylated (U-MSP) alleles of the p15, p16, p18, and RB genes was used to study five leukemic cell lines, 50 acute myeloid leukemia (AML) and 25 acute lymphoblastic leukemia (ALL) samples. None of the leukemic cell lines showed p18 and RB methylation. p15 was methylated in Raji, while p16 was methylated in U937 and Raji. In NB4 and Jurkat, both alleles of p15 and p16 appeared to be deleted. At diagnosis, p15 methylation occurred in 29 (58%) AML patients, and 10 (40.0%) ALL patients. p16 methylation occurred in two (4%) AML and two (8%) ALL patients. Only one each of AML and ALL patients had concurrent p15 and p16 methylation. None of the patients had methylation of p18 or RB. In AML, p15 methylation was associated with M2 subtype (p=0.018). Patients with and without p15 methylation had similar complete remission (CR) rates and projected 5-year overall survival (OS) or disease-free survival (DFS). Therefore, methylation inactivation of the INK4/CDK/RB pathway in leukemia involved primarily p15 and occasionally p16, but not p18 or RB. In AML, p15 gene methylation was associated with the M2 subtype, but was not prognostic for CR, OS, or DFS.

Hann WC, Weinberg RA (2002) Rules for making human tumor cells. N Engl J Med 347:1593–1603CrossRefPubMed

Malumbres M, Barbacid M (2001) To cycle or not to cycle: a critical decision in cancer. Nat Cancer Rev 1:222–231CrossRef

Hirama T, Koeffler HP (1995) Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 86:841–854PubMed

Sherr CJ (1994) Cancer cell cycle. Science 274:1672–1677CrossRef

Roussel MF (1999) The INK4 family of cell cycle inhibitors in cancer. Oncogene 18:5311–5317CrossRefPubMed

Jeffrey PD, Tong L, Pavletich NP (2000) Structural basis of inhibition of CDK-cyclin complexes by INK4 inhibitors. Genes Dev 14:3115–3125CrossRefPubMed

Sherr CJ, Roberts JM (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13:1501–1512PubMed

Baylin SB, Herman JG, Graff JR, VertinoPM, Issa JP (1998) Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 72:141–196PubMed

Robertson KD, Wolffe AP (2000) DNA methylation in health and disease. Nat Rev 1:11–19CrossRefPubMed

10.

Singal R, Ginder GD (1999) DNA methylation. Blood 93:4059–4070PubMed

11.

Chim CS, Liang R, Kwong YL (2002) Gene promoter hypermethylation in hematologic malignancies. Hematol Oncol 20:167–176CrossRefPubMed

12.

Siegfried Z, Eden S, Mendelsohn M, Feng X, Tsuberi BZ, Cedar H (1999) DNA methylation represses transcription in vivo. Nat Genet 22:203–206PubMed

13.

Jones PA, Laird PW (1999) Cancer epigenetics comes of age. Nat Genet 21:163–167CrossRefPubMed

14.

Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. (1976) Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 33:451–458PubMed

15.

Second MIC Cooperative Study Group (1988) Morphologic, immunologic and cytogenetic (MIC) working classification of the acute myeloid leukaemias. Br J Haematol 68:487–494PubMed

16.

Chim CS, Tam C, Liang R, Kwong YL (2001) P15 and P16 gene methylation in adult acute leukemia: lack of prognostic significance. Cancer 91:2222–2229CrossRefPubMed

17.

Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 93:9821–9826CrossRefPubMed

18.

Chim CS, Liang R, Tam C, Kwong YL (2001) P15 and P16 promoter methylation in acute promyelocytic leukemia. J Clin Oncol 19:2033–2040PubMed

19.

Roncalli M, Bianchi P, Bruni B, Laghi L, Destro A, Di Gioia S, Gennari L, Tommasini M, Malesci A, Coggi G (2002) Methylation framework of cell cycle gene inhibitors in cirrhosis and associated hepatocellular carcinoma. Hepatology 36:427–432CrossRefPubMed

20.

Simpson DJ, Hibberts NA, McNicol AM, Clayton RN, Farrell WE (2000) Loss of pRb expression in pituitary adenomas is associated with methylation of the RB1 CpG island. Cancer Res 60:1211–1216PubMed

21.

Zindy F, van Deursen J, Grosveld G, Sherr CJ, Roussel MF (2000) INK4d-deficient mice are fertile despite testicular atrophy. Mol Cell Biol 20:372–378PubMed

22.

Pabst T, Mueller BU, Zhang P, Radomska HS, Narravula S, Schnittger S, Behre G, Hiddemann W, Tenen DG (2001) Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet 27:263–270CrossRefPubMed

23.

Chim CS, Wong AS, Kwong YL (2002) Infrequent hypermethylation of CEBPA promotor in acute myeloid leukaemia. Br J Haematol 119:988–990CrossRefPubMed

24.

Preisler HD, Li B, Chen H, Fisher L, Nayini J, Raza A, Creech S, Venugopal P (2001) P15INK4B gene methylation and expression in normal, myelodysplastic, and acute myelogenous leukemia cells and in the marrow cells of cured lymphoma patients. Leukemia 15:1589–1595CrossRefPubMed

25.

Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA (1994) Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368:753–756

26.

Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS, Johnson BE, Skolnick MH (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436–440PubMed

27.

Drexler HG (1998) Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia 12:845–859CrossRefPubMed

28.

Ng MH, Chung YF, Lo KW, Wickham NW, Lee JC, Huang DP (1997) Frequent hypermethylation of p16 and p15 genes in multiple myeloma. Blood 89:2500–2506PubMed

29.

Sauerbrey A, Stammler G, Zintl F, Volm M (1998) Expression of the retinoblastoma tumor suppressor gene (RB-1) in acute leukemia. Leuk Lymphoma 28:275–283PubMed

30.

Jamal R, Gale RE, Shaun N, Thomas B, Wheatley K, Linch DC (1996) The retinoblastoma gene (rb1) in acute myeloid leukaemia: analysis of gene rearrangements, protein expression and comparison of disease outcome. Br J Haematol 94:342–351PubMed

31.

Hangaishi A, Ogawa S, Imamura N, Miyawaki S, Miura Y, Uike N, Shimazaki C, Emi N, Takeyama K, Hirosawa S, Kamada N, Kobayashi Y, Takemoto Y, Kitani T, Toyama K, Ohtake S, Yazaki Y, Ueda R, Hirai H (1996) Inactivation of multiple tumor-suppressor genes involved in negative regulation of the cell cycle, MTS1/p16INK4A/CDKN2, MTS2/p15INK4B, p53, and Rb genes in primary lymphoid malignancies. Blood 87:4949-4958

32.

Barbosa de Melo M, Costa FF, Saad ST, Lorand-Metze I, Bordin S, Ahmad NN (1998) Molecular analysis of the retinoblastoma (RB1) gene in acute myeloid leukemia patients. Leuk Res 22:787–792CrossRefPubMed

33.

Guan KL, Jenkins CW, Li Y, Nichols MA, Wu X, O'Keefe CL, Matera AG, Xiong Y (1994) Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev 8:2939–2952PubMed

34.

Franklin DS, Godfrey VL, Lee H, Kovalev GI, Schoonhoven R, Chen-Kiang S, Su L, Xiong Y (1998) CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. Genes Dev 12:2899–2911PubMed

35.

Latres E, Malumbres M, Sotillo R, Martin J, Ortega S, Martin-Caballero J, Flores JM, Cordon-Cardo C, Barbacid M (2000) Limited overlapping roles of P15(INK4b) and P18(INK4c) cell cycle inhibitors in proliferation and tumorigenesis. EMBO J 19:3496–3506PubMed

36.

Takeuchi S, Bartram CR, Seriu T, Miller CW, Tobler A, Janssen JW, Reiter A, Ludwig WD, Zimmermann M, Schwaller J, et al. (1995) Analysis of a family of cyclin-dependent kinase inhibitors: p15/MTS2/INK4B, p16/MTS1/INK4A, and p18 genes in acute lymphoblastic leukemia of childhood. Blood 86:755–760PubMed

37.

Nakamaki T, Kawamata N, Schwaller J, Tobler A, Fey M, Pakkala S, Lee YY, Kim BK, Fukuchi K, Tsuruoka N, et al. (1995) Structural integrity of the cyclin-dependent kinase inhibitor genes, p15, p16 and p18 in myeloid leukaemias. Br J Haematol 91:139–149PubMed

38.

Maesawa C, Tamura G, Nishizuka S, et al. (1996) Inactivation of the CDKN2 gene by homozygous deletion and de novo methylation is associated with advanced stage esophageal squamous cell carcinoma. Cancer Res 56:3875–3878PubMed

39.

Tang X, Khuri FR, Lee JJ, Kemp BL, Liu D, Hong WK, Mao L (2000) Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J Natl Cancer Inst 92:1511–1516CrossRefPubMed

40.

Esteller M, Gaidano G, Goodman SN, Zagonel V, Capello D, Botto B, Rossi D, Gloghini A, Vitolo U, Carbone A, Baylin SB, Herman JG (2002) Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J Natl Cancer Inst 94:26–32PubMed

41.

Wijermans P, Lubbert M, Verhoef G, et al. (2000) Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 18:956–962PubMed

42.

Silverman LR, Demakos EP, Bercedis L, et al. (2002) A randomized controlled trial of azacitidine in patients with myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 20:2429–2440PubMed

Titel: Epigenetic inactivation of INK4/CDK/RB cell cycle pathway in acute leukemias
verfasst von: C. S. Chim
A. S. Y. Wong
Y. L. Kwong
Publikationsdatum: 01.12.2003
Verlag: Springer-Verlag
Erschienen in: Annals of Hematology / Ausgabe 12/2003
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-003-0744-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2003

A randomized study of intermediate as compared with high doses of interferon-alpha for chronic myeloid leukemia: no differences in cytogenetic responses

Hereditary spherocytosis associated with mutations in HFE gene

High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities

Treatment advances in adult immune thrombocytopenic purpura

Dynamics of circulating t(14;18)-positive cells during first-line and subsequent lines of treatment in follicular lymphoma